Advertisement

Picture Berlin Partner Top News CRIPSR Repairs Immune Cells 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 4486 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 43 44 45  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
PerkinElmer–Varex Imaging: investment, 201612–201705 acquisition $276m cash of PE’s medical imaging business by Varex Imaging (Varian Medical Systems) 2016-12-22
C.B.S. Scientific–Genetrix (ES): investment, 201612 acquisition $900k of C.B.S. Scientific Company for $540k cash + $360k in shares by Sygnis AG 2016-12-21
Purdue Pharma–Celltrion: rituximab, 201612– acquisition distribution rights for UK+IE+DE+IT+Benelux for biosimilar Truxima by Mundipharma 2016-12-20
Xpand Biotechnology–Kuros: investment, 201612 merger acquisition of Xpand Biotechnology BV by Kuros Biosciences AG for up to 2.105m new Kuros shares 2016-12-19
KKR–Lonza: investment, 201612–201707 acquisition of Capsugel for $5.5b in cash from KKR by Lonza 2016-12-15
Noxxon–Merck (US): cancer immunotherapy, 201612– collab clinical research combi of Keytruda + NOX-A12 in metastatic colorectal + pancreatic cancer 2016-12-15
Univercells–Gates Foundation: grant, 201612 grant $12m to reduce costs of vaccines for developing countries in collab w Batavia + Natrix 2016-12-15
Carpegen–Lifescience Business Consulting: business consulting, 201612 supply portfolio/market analysis for sale of Gyronimo RT-PCR platform to Curetis 2016-12-13
Carpegen–Osborne Clarke: legal services, 201612 supply legal advisor for sale of Carpegen’s Gyronimo RT-PCR platform to Curetis 2016-12-13
Numares–Ruth Group: public relations, 201612 service existent US PR + IR by The Ruth Group 2016-12-08
Acticor Biotech–Merck (DE): rec protein production, 201612– supply Provantage End-to-End Services for developm + manufacturing of Fab 2016-12-05
Boehringer–Bruker: mass spectrometer, 201612 supply of MALDI PharmaPulse 2.0 incl rapifleX MALDI-TOF System in Biberach 2016-12-01
Medigene–Coulter Partners: recruitment services, 201612 supply service placement of Thomas Taapken as new CFO of Medigene 2016-12-01
Phlexglobal–Vitruvian Partners: investment, 201612 investment by VIP II 2016-12-01
Roche–Bruker: mass spectrometer, 201612 supply of MALDI PharmaPulse 2.0 incl rapifleX MALDI-TOF System to Genentech 2016-12-01
GeneWerk–GenoSafe: gene/cell therapy services, 201611– collab framwork agreem to offer combined research services 2016-11-29
T3 Pharmaceuticals–OTHER: investment, 201611 1st financing round from private Swiss investors 2016-11-23
OSE Immunotherapeutics–Selexis: cell line development, 201611– supply service access to research cell banks from SUREtechnology platform 2016-11-15
Evotec–Univ Oxford: drug discovery, 201611– collab partnership LAB282 for early-stage projects out of Oxford Univ with OUI + OSI 2016-11-10
Takeda–AstraZeneca: digital pathology, 201611– collab using Definiens' newly launched VeriTrova cloud-based solution 2016-11-07
Aimmune Therapeutics–Nestlé: investment, 201611 equity investment $145m w 7.6m shares at $19.2/share by Nestlé Health Science 2016-11-04
Nestlé–Aimmune Therapeutics: immunotherapy, 201611– strategic collab to develop + commercialise food allergy therapies w Neslé Health Science 2016-11-04
Actelion–Reveragen: vamorolone, 201611– excl license option for Actelion 2016-11-03
AMP-Therapeutics–EnBiotix: investment, 201611 acquisition of AMPT via asset acquisition by newly established EnBiotix GmbH 2016-11-03
Xencor–Selexis: cell line development, 201611– supply service strategic agreem for SUREtechnology for developm of multi-specific antibodies 2016-11-03
Leo Pharma–MorphoSys: therapeutic antibodies, 201611– collab strategic alliance to develop ABs in dermatology using Ylanthia technology 2016-11-02
Q Laboratories–Bruker: mass spectrometer, 201611 supply MALDI Biotyper 2016-11-01
Science 37–Novartis: investment, 201610 financing round Series B totalling $31m incl existing + co-investor dRx Capital 2016-10-18
Science 37–SEVERAL: investment, 201610 financing round Series B $31m led by Redmile Group + incl Lux Capital + dRx Capital + SGBV 2016-10-18
ObsEva–SEVERAL: investment, 201610–201701 IPO $96.75m+$14.513m w 645k+967.5k common shares at $15/share at Nasdaq Global Select Market 2016-10-17
Max Planck–Labfolder: electronic lab notebook, 201610– supply license for up to 11k MPI researchers using Labfolder s/w 2016-10-12
UgiSense–SEVERAL: investment, 201610 first financing round €1.2m from private investors 2016-10-12
Selexis–Sam Brown: public relations, 201610 service existent by Sam Brown Inc 2016-10-10
Noxxon–OTHER: investment, 201609 listing of ordinary shares on Alternext Paris [no new shares issued] 2016-09-30
Noxxon–SEVERAL: investment, 201609 private placement just prior to listing of ordinary shares on Alternext Paris 2016-09-30
Boehringer–Hospital Corp of America: clinical research, 201609– collab clinical developm of combi of 2 checkpoint inhibitors w Sarah Cannon Research 2016-09-29
ICMP–Qiagen: MDx forensics, 201609– collab developm NGS workflow for identification of missing persons 2016-09-29
Boehringer–ViraTherapeutics: cancer immunotherapy, 201609– long-term collab up to €210m to develop oncolytic virus platform + products 2016-09-28
Noxxon–NewCap: public relations, 201609 service existent by NewCap 2016-09-28
Evotec–France (govt): cancer drug discovery, 201609– research collab with Inserm in translational oncology 2016-09-22
Polyplus-transfection–ArchiMed: investment, 201609 acquisition of majority stake by ArchiMed 2016-09-19
PaxVax–Leukocare: drug formulation technology, 201609– license to SPS technology for one live viral vaccine product of PaxVax 2016-09-13
Inflazome–Fountain Healthcare Partners: investment, 201609 financing round Series A totalling $17m incl founding investor FHP 2016-09-12
Inflazome–Novartis: investment, 201609 financing round Series A totalling $17m incl founding investor Novartis Venture Fund 2016-09-12
Inflazome–SEVERAL: investment, 201609 financing round Series A $17m from Novartis Venture Fund + Fountain Healthcare Partners 2016-09-12
Curetis–Siemens: GEAR database, 201609 acquisition €na of ww rights to GEAR database + related IP + know-how by Curetis from STA 2016-09-07
ViraTherapeutics–Boehringer: investment, 201809 acquisition of all remaining shares of ViraTby BI with total transaction value of €210m 2016-08-01
Pro Farma–Recordati: investment, 201607 acquisition CHF16m 100% of Pro Farma AG by Recordati 2016-07-14
Delenex–Cell Medica: investment, 201607 acquisition €na of Delenex Pharmaceuticals AG by Cell Medica 2016-07-12
Charles River–Caprotec: CCMS technology, 201606 collab use of CCMS tech to identify protein targets relevant for phenotypic drug candidate responses 2016-06-29
Storm Therapeutics–Merck (DE): investment, 201606 financing round Series A totalling £12m incl investor Merck Ventures 2016-06-28
Storm Therapeutics–SEVERAL: investment, 201606 financing round Series A £12m with CIC + Merck Ventures + Pfizer Venture + Touchstone Innovations 2016-06-28
Cosmo Pharmaceuticals–Paion: remimazolam, 201606– license excl €10m upfront + €42.5m milestones + royalties for developm + commercialisation in US 2016-06-24
Grünenthal–AstraZeneca: lesinurad, 201606– license excl for Europe + Latin America to Zurampic + fixed dose combi of lesinurad + allopurinol 2016-06-02
Celonis–SEVERAL: investment, 201606 financing round Series A $27.5m 2016-06-01
Nouscom–Life Sciences Partners: investment, 201605 financing round Series A totalling €12m co-led by LSP + Versant Ventures 2016-05-17
Nouscom–Versant Ventures: investment, 201605 financing round Series A totalling €12m co-led by LSP + Versant Ventures 2016-05-17
LabCorp–Epigenomics: molecular diagnostics cancer test, 201605– distribution LabCorp to offer Epi proColon test in the US 2016-05-09
G-Therapeutics–Gimv: investment, 201604 financing round Series A totalling €26m incl co-investor Gimv 2016-04-19
Labiotech.eu–WestTech Ventures: investment, 201602 seed financing round totalling low €6-digit incl lead investor WestTech Ventures 2016-02-03
Amgen–Biocartis: molecular companion diagnostics, 201712– collab €na developm liquid biopsy Idylla RAS CDx test for Vectibix 2016-01-07
Mecuris–Bavaria (govt): investment, 2016c seed financing round from Bayern Kapital + HTGF 2016-01-01
Mecuris–High-Tech Gründerfonds: investment, 2016c seed financing round from Bayern Kapital + HTGF 2016-01-01
Mecuris–SEVERAL: investment, 2016c seed financing round from Bayern Kapital + HTGF 2016-01-01
Merus–Minapharm: GlymaxX technology, 2016– non-excl license agreem for use of GlymaxX for Biclonics pipeline from ProBioGen AG 2016-01-01
MicrobeDx–Microfluidic ChipShop: microfluidics technology, 2016– collab developm + production of pharmacodiagnostic test systems 2016-01-01
Probiodrug–Crossbeta Biosciences: biomarker research, 2016– collab developm Alzheimer biomarker to support Probiodrug’s clinical AD program 2016-01-01
Storm Therapeutics–Evotec: drug discovery services, 2016– supply service HTS + structural biology to identify hits for 2 RNA modulating targets 2016-01-01
Bridgepoint–KKR: investment, 201512 acquisition €na of LGC by KKR from Bridgepoint 2015-12-08
Omeicos–Germany (govt): grant, 201511– BMBF research grant €1.7m 2015-11-02
MTIP MedTech Innovation Partners–SEVERAL: investment, 201511–201604 1st closing CHF30m of 1st MTIP Fund 2015-11-01
Tusk Therapeutics–SEVERAL: investment, 201511 financing round Series A €30m 2015-11-01
Arvinas–SEVERAL: investment, 201510 financing round Series B $41.6m led by RA Capital Management 2015-10-21
Science 37–Novartis: investment, 201510 financing round Series A totalling $6.5m co-led by Lux Capital + dRx Capital 2015-10-20
Science 37–SEVERAL: investment, 201510 financing round Series A $6.5m co-led by Lux Capital + dRx Capital 2015-10-20
Zavante Therapeutics–SEVERAL: investment, 201510 seed financing round 2015-10-09
Roche–Arvinas: protein degradation drugs, 201510– strategic license multi-year for PROTAC technology to Genentech 2015-10-01
Baxalta–Novimmune: therapeutic antibodies, 201509– collab RnD €na bispecific antibodies for hemophilia A 2015-09-02
Protembis–SEVERAL: investment, 201507 seed financing round 7-digit € incl Innovationsstarter Fonds + Geratherm + angel investors 2015-07-28
AdvanDx–OpGen: investment, 201507 merger acquisition by AdvanDx for 682k shares of OpGen common stock 2015-07-14
ViraTherapeutics–Austria (govt): investment, 201506 financing round Series A 1st closing totalling €3.6m incl co-investor aws 2015-06-23
ViraTherapeutics–Boehringer: investment, 201506 financing round Series A 1st closing totalling €3.6m co-led by BIVF + EMBL Ventures 2015-06-23
ViraTherapeutics–EMBL: investment, 201506 financing round Series A 1st closing totalling €3.6m co-led by BIVF + EMBL Ventures 2015-06-23
Cyclenium–Haplogen: virostatic agents, 201505– collab drug discovery small molecule macroycle inhibitors using CMRT technology 2015-05-01
Blueberry Therapeutics–SEVERAL: investment, 201504 financing round $1.75m from UK + Swiss investors 2015-04-08
Macrolide–Bertarelli Group: investment, 201503 financing round Series A totalling $22m inc co-lead investor Gurnet Point Capital 2015-03-04
Macrolide–GSK: investment, 201503 financing round Series A totalling $22m inc co-lead investor SROne 2015-03-04
Macrolide–Novartis: investment, 201503 financing round Series A totalling $22m inc co-lead investor Novartis Venture Fund 2015-03-04
Macrolide–Roche: investment, 201503 financing round Series A totalling $22m inc co-lead investor Roche Ventures 2015-03-04
Macrolide–SEVERAL: investment, 201503 financing round Series A $22m led by NVF + Gurnet Point + Roche Ventures + SR One 2015-03-04
OpGen–SEVERAL: investment, 201503–201505 IPO $17.1m+$2.565m with 2.85m+427.5k units consisting of 1 share + 1 warrant at $6/unit 2015-03-03
Genenta Science–SEVERAL: investment, 201503 financing round Series A €10m 2015-03-01
R2R Biofluidics project–EU (govt): grant, 201502–201901 H2020 grant €6.4m out of total budget of €7.9m 2015-02-01
Boehringer–Vanderbilt Univ: Ras inhibitors, 201703– collab expansion RnD small-molecule KRAS inhibitors for cancer 2015-01-13
Aquila Biolabs–SEVERAL: investment, 2015 seed financing round 7-digit € 2015-01-01
Atomwise–SEVERAL: investment, 2015 seed financing round incl Y Combinator + Khosla Ventures + DJF 2015-01-01
Biocentric–Hain Lifescience: investment, 2015 acquisition of Biocentric by Hain 2015-01-01
GreenBone–SEVERAL: investment, 2015 seed financing round €3m from ZernikeMeta Ventures + Italian Angels for Growth + private investors 2015-01-01
Jecure Therapeutics–Versant Ventures: investment, 2015 seed financing from founding investor Versant Ventures 2015-01-01
KBI BioPharma–JSR Corp: investment, 2015 acquisition of KBI BioPharma Inc by JSR Corp 2015-01-01
next pagenext page 1 2 3 ... 43 44 45  next pagenext page



Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x300px

» top